
|Articles|March 1, 2018
- Pharmaceutical Executive-03-01-2018
- Volume 38
- Issue 3
Pharmaceutical Executive, March 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 8 years ago
Pharma: Meet Your New Neighborsalmost 8 years ago
Risk Sharing, Italian Stylealmost 8 years ago
The Quest to Measure Upalmost 8 years ago
Full Disclosure Demanded for Pharma Industryalmost 8 years ago
Setting the Standard: William Soliman, ACMAalmost 8 years ago
The Law of Unintended Consequencesalmost 8 years ago
Pricing Turning Point: The Case for Innovating Pharma’s Modelalmost 8 years ago
Showdown Nears on Europe Research Incentivesalmost 8 years ago
The Personalized Genetic Profile: It’s Time to Alignalmost 8 years ago
Country Report: IndiaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5




